30929-67-0

Basic information

• Product Name: 5-AMino-1-cyclopentyl-1H-pyrazole-4-carbonitrile
• Synonyms: 5-AMino-1-cyclopentyl-1H-pyrazole-4-carbonitrile
• CAS NO: 30929-67-0
• Molecular Formula: C₉H₁₂N₄
• Molecular Weight: 176.21838
• Mol File: 30929-67-0.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-AMino-1-cyclopentyl-1H-pyrazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMino-1-cyclopentyl-1H-pyrazole-4-carbonitrile(30929-67-0)
• EPA Substance Registry System: 5-AMino-1-cyclopentyl-1H-pyrazole-4-carbonitrile(30929-67-0)

Safety Data

• Hazardous Substances Data: 30929-67-0(Hazardous Substances Data)

Usage

General Description

5-Amino-1-cyclopentyl-1H-pyrazole-4-carbonitrile is a chemical compound with the molecular formula C8H9N5. It is a pyrazole derivative with a cyclopentyl group and a carbonitrile functional group. 5-AMino-1-cyclopentyl-1H-pyrazole-4-carbonitrile has potential applications in the pharmaceutical industry, particularly in the development of new drugs. It may also be used as a building block in organic synthesis for the production of various compounds. The specific properties and potential uses of 5-Amino-1-cyclopentyl-1H-pyrazole-4-carbonitrile depend on its chemical structure and reactivity, making it a subject of interest for researchers and industry professionals in the field of chemistry and pharmaceuticals. Further studies and experimentation may reveal more about its potential applications and utility in various fields.

Upstream product

• 672-81-1 2-(methoxymethylene)malononitrile 
• 24214-72-0 cyclopentylhydrazine hydrochloride 
• 123-06-8 Ethoxymethylenemalononitrile 
• 30923-92-3 cyclopentylhydrazine 
• 645372-27-6 cyclopentyl hydrazine dihydrochloride 
• 137-43-9 Cyclopentyl bromide 
• 16617-46-2 3-Amino-4-cyanopyrazole 

Downstream Products

• 1236858-90-4 1-cyclopentyl-6-[(1S)-1-(3-phenoxyazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1236858-92-6 1-cyclopentyl-6-[(1R)-1-(3-phenoxyazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1236859-40-7 1-cyclopentyl-6-[1-(3-phenylpyrrolidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1402155-52-5 C₂₃H₂₉N₅O₃ 
• 1402155-53-6 C₂₁H₂₅N₅O₂ 
• 1548588-80-2 6-[(4-chlorophenyl)thio]methyl-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
• 1548588-39-1 1-cyclopentyl-6-(phenoxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 

Relevant articles and documents

Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease

Phosphodiesterase-9 (PDE9) is a promising target for treatment of Alzheimer’s disease (AD). To discover multifunctional anti-AD agents with capability of PDE9 inhibition and antioxidant activity, a series of novel pyrazolopyrimidinone derivatives, couplin

Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles

Here, we present a series of dual-target phosphodiesterase 9 (PDE9) and histone deacetylase (HDAC) inhibitors devised as pharmacological tool compounds for assessing the implications of these two targets in Alzheimer's disease (AD). These novel inhibitors were designed taking into account the key pharmacophoric features of known selective PDE9 inhibitors as well as privileged chemical structures, bearing zinc binding groups (hydroxamic acids and ortho-amino anilides) that hit HDAC targets. These substituents were selected according to rational criteria and previous knowledge from our group to explore diverse HDAC selectivity profiles (pan-HDAC, HDAC6 selective, and class I selective) that were confirmed in biochemical screens. Their functional response in inducing acetylation of histone and tubulin and phosphorylation of cAMP response element binding (CREB) was measured as a requisite for further progression into complete in vitro absorption, distribution, metabolism and excretion (ADME) and in vivo brain penetration profiling. Compound 31b, a selective HDAC6 inhibitor with acceptable brain permeability, was chosen for assessing in vivo efficacy of these first-in-class inhibitors, as well as studying their mode of action (MoA).

N-substituted pyrazolo [3, 4-d] pyrimidone compound and preparation method and application thereof

The invention discloses a preparation method and application of a N-substituted pyrazolo [3, 4-d] pyrimidone compound. The compound has the structure shown in formula 1, wherein R is a cyclic or non cyclic fatty alkyl group, a heterocyclic group, an acyl-